ClinicalTrials.gg
CompletedNCT05386589Updated Jan 28, 2025Results posted

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

A Phase 1 interventional study of Molnupiravir in Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of N-hydroxycytidine (NHC) following a single oral dose of molnupiravir in participants 18 to 75 years (inclusive) with moderate hepatic impairment and healthy matched controls.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Has a ≥18.5 and ≤35 kg/m2
  • Diagnosis of chronic (>6 months) stable Hepatic Impairment (HI) with features of cirrhosis due to any etiology (Moderate HI arm only)
  • Has a score on the scale ranging from 7 to 9 (Moderate HI arm only)
  • In good health (except for Moderate HI)

Exclusion criteria

Exclusion Criteria:

  • Anticipated survival of \<3 months (Moderate HI arm only)
  • Received antiviral and/or immune modulating therapy (Moderate HI only) for Virus (HBV) or Virus (HCV) within 90 days prior to study start
  • History of abnormalities or diseases (Healthy matched arm only).
  • History of cancer
  • Major surgery and/or donated or lost 1 unit of blood
  • Taking medications to treat chronic medical conditions and has not been on a stable regimen for at least 1 month (Moderate HI arm only) and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours after administration of the study drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment

    Participants with moderate hepatic impairment received a single oral dose of molnupiravir 800 mg on Day 1.

    Drug: Molnupiravir

  • Experimental
    Healthy-Matched Control Group

    Healthy matched participants received a single oral dose of molnupiravir 800 mg on Day 1.

    Drug: Molnupiravir

Interventions

  • Four 200 mg capsules administered orally as a single dose

    Also known as: MK-4482,, MOV, EIDD-2801

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC)

    The plasma AUC0-∞ of NHC is reported.

    Time frame: Day 1: Predose and 0.5, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose

  2. Maximum Plasma Concentration (Cmax) of NHC

    The plasma Cmax of NHC is reported.

    Time frame: Day 1: Predose and 0.5, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose

Secondary outcomes

  1. Number of Participants Experiencing ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~ 14 days

07

Results

Posted May 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneModerate Hepatic ImpairmentHealthy-Matched Control Group
Started77
Completed77
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC)

The plasma AUC0-∞ of NHC is reported.

Time frame:
Day 1: Predose and 0.5, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC)
hr*ng/mLModerate Hepatic ImpairmentHealthy-Matched Control Group
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC)8930 (6560 to 12100)10900 (8510 to 14000)
PrimaryMaximum Plasma Concentration (Cmax) of NHC

The plasma Cmax of NHC is reported.

Time frame:
Day 1: Predose and 0.5, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of NHC
ng/mLModerate Hepatic ImpairmentHealthy-Matched Control Group
Maximum Plasma Concentration (Cmax) of NHC3660 (2730 to 4900)3790 (3260 to 4420)
SecondaryNumber of Participants Experiencing ≥1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to ~ 14 days
Reported as:
Count of participants · Participants
Number of Participants Experiencing ≥1 Adverse Event (AE)
ParticipantsModerate Hepatic ImpairmentHealthy-Matched Control Group
Number of Participants Experiencing ≥1 Adverse Event (AE)01

Adverse events

Collected over Up to ~14 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moderate Hepatic Impairment0/7 (0%)0/7 (0%)0/7 (0%)
Healthy-Matched Control Group0/7 (0%)0/7 (0%)1/7 (14.3%)
Most frequent other events
Most frequent other events
EventModerate Hepatic ImpairmentHealthy-Matched Control Group
Respiratory disorderRespiratory, thoracic and mediastinal disorders0/71/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Moderate Hepatic ImpairmentHealthy-Matched Control GroupTotal
Mean54.0 ± 10.254.6 ± 2.954.3 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Moderate Hepatic ImpairmentHealthy-Matched Control GroupTotal
Female336
Male448
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Moderate Hepatic ImpairmentHealthy-Matched Control GroupTotal
Hispanic or Latino6410
Not Hispanic or Latino134
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Moderate Hepatic ImpairmentHealthy-Matched Control GroupTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American022
White6511
More than one race000
Unknown or Not Reported000
08

Study locations

3 sites
  • Research Centers of America ( Hollywood ) ( Site 0002)
    Hollywood, Florida 33024, United States
  • Clinical Pharmacology of Miami ( Site 0003)
    Miami, Florida 33014, United States
  • Thomas Jefferson University - Pharmacology and Experimental Therapeutics ( Site 0001)
    Philadelphia, Pennsylvania 19107, United States
09

References and documents

Publications

  • Duncan KE, Carstens RP, Butterfield KL, Jin Y, Inbody LR, Schaeffer AK, Matthews CZ, Zhao T, Patel S, Maas BM, Cheng MH, Stoch SA. Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairment. Clin Transl Sci. 2024 Dec;17(12):e70073. doi: 10.1111/cts.70073. PubMed 39601078 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Dec 2022, 6 months.

Results were first posted in May 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2022
First posted
May 23, 2022
StartActual
Jun 14, 2022
Primary completionActual
Dec 18, 2022
CompletionActual
Jan 5, 2023
Results first posted
May 9, 2024
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05386589
Responsible party
Sponsor
First posted
May 23, 2022
Start date
Jun 14, 2022
Primary completion
Dec 18, 2022
Completion
Jan 5, 2023
Results posted
May 9, 2024
Last update
Jan 28, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion